Enhances catalytic activity and stability of rhArg1 using non-conserved residue mutations, suggesting improved therapeutic potential.
Arginase 1 deficiency is a rare inherited metabolic disorder characterized by progressive neurological dysfunction. Although recombinant human arginase 1 (rhArg1) has been investigated as a therapeutic enzyme, its clinical potential is limited by insufficient catalytic activity and stability. In this study, we applied an evolutionary conservation-guided design strategy to enhance rhArg1 activity by targeting low-conservation residues within the catalytic pocket. Seven candidate sites were identified, and 29 variants were generated by site-directed and combinatorial mutagenesis. Under 2 mM Mn²⁺ conditions, several mutants (N139K, Q143K, and Q143S) exhibited 1.4-1.6 fold increases in kcat relative to the wild type. Notably, under Mn²⁺-free conditions, the double mutant T136D/Q143V showed a 1.5-fold increase in kcat and a 73% improvement in kcat/KM. Molecular dynamics simulations revealed that these mutations enhance catalytic performance by promoting near-attack conformations. This work demonstrates an effective rational strategy for improving rhArg1 catalytic efficiency and stability, supporting its therapeutic development.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: